FibroGen (FGEN) Price Target Increased by 40.00% to 1.79

5d ago, source: Hosted on MSN

The average one-year price target for FibroGen (NasdaqGS:FGEN) has been revised to 1.78 / share. This is an increase of 40.00 ...

FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape

on MSN ago, source:

FibroGen Inc (NASDAQ:FGEN) announced topline data from the Fortis Therapeutics-sponsored Phase 1 study of FG-3246 (also known ...

FibroGen, former employees settle dispute over alleged trade secrets theft

3d ago, source: FiercePharma

As for FibroGen’s roxadustat, the drug has fallen victim to a string of setbacks in the U.S. that culminated in late February ...

FibroGen, Inc. (FGEN)

4d ago, source: Yahoo Finance

SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a corporate presentation at the 23rd ...

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

20d ago, source: Business Insider

FibroGen, Inc. is a biopharmaceutical company focused on accelerating the development of novel therapies at the frontiers of cancer biology. Pamrevlumab, a fully human anti-CTGF monoclonal ...

ADC FG-3246 May Show Promise in Advanced Prostate Cancer

4d ago, source: Cure Today

Topline data has been released from a trial of antibody-drug conjugate FG-3246 for patients with pretreated, metastatic ...

FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis

1mon ago, source: ADVFN

FibroGen, Inc. (NASDAQ: FGEN) today announced topline results from its Phase 3 ZEPHYRUS-1 trial evaluating the safety and efficacy of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF).

FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape

19d ago, source: Business Insider

FibroGen Inc (NASDAQ:FGEN) announced topline data from the Fortis Therapeutics-sponsored Phase 1 study of FG-3246 (also known as FOR46), a potential first-in-class anti-CD46 antibody drug ...

FibroGen (FGEN) Price Target Increased by 40.00% to 1.79

5d ago, source: Nasdaq

FibroGen Background Information (This description is provided by the company.) FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of ...

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

20d ago, source: Stockhouse

FG-3246 is an investigational drug and not approved for marketing by any regulatory authority. FibroGen, Inc. is a biopharmaceutical company focused on accelerating the development of novel therapies ...